149 related articles for article (PubMed ID: 31477806)
1. Companion gene mutations and their clinical significance in AML with double mutant CEBPA.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Teng W; Cao P; Nie D; Ma X; Wang T; Lu P; Liu H
Cancer Gene Ther; 2020 Aug; 27(7-8):599-606. PubMed ID: 31477806
[TBL] [Abstract][Full Text] [Related]
2. The clinical characteristics and prognosis of cytogenetically normal AML with single mutations of CEBPA.
Kang Y; Chen X; Fang F; Zhang L; Wang J; Tian C; Guo W; Xu J; Ren H; Muyey DM; Tan Y; Xu Z; Wang H
Int J Lab Hematol; 2021 Dec; 43(6):1424-1431. PubMed ID: 34216417
[TBL] [Abstract][Full Text] [Related]
3. The role of different genetic subtypes of CEBPA mutated AML.
Fasan A; Haferlach C; Alpermann T; Jeromin S; Grossmann V; Eder C; Weissmann S; Dicker F; Kohlmann A; Schindela S; Kern W; Haferlach T; Schnittger S
Leukemia; 2014 Apr; 28(4):794-803. PubMed ID: 24056881
[TBL] [Abstract][Full Text] [Related]
4. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
[TBL] [Abstract][Full Text] [Related]
5. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
6. [Clinical Characteristics and Prognosis of Acute Myeloid Leukemia Patients with
Shan RQ; Huang S; Gu ZY; Wang N; Liu DH; Dou LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):327-334. PubMed ID: 38660832
[TBL] [Abstract][Full Text] [Related]
7. Differential Implications of CSF3R Mutations in t(8;21) and CEBPA Double Mutated Acute Myeloid Leukemia.
Wang B; Wen L; Wang Z; Chen S; Qiu H
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):393-404. PubMed ID: 34975010
[TBL] [Abstract][Full Text] [Related]
8. [Clinical features and prognostic factors in adult acute myeloid leukemia patients with FLT3-ITD and CEBPA gene co-mutation].
Pei RR; Zhang RH; Yu JF; Jiang ZX; Sun H; Wan DM; Xie XS; Liu YF; Li T; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):297-301. PubMed ID: 32447933
[No Abstract] [Full Text] [Related]
9. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
Tarlock K; Lamble AJ; Wang YC; Gerbing RB; Ries RE; Loken MR; Brodersen LE; Pardo L; Leonti A; Smith JL; Hylkema TA; Woods WG; Cooper TM; Kolb EA; Gamis AS; Aplenc R; Alonzo TA; Meshinchi S
Blood; 2021 Sep; 138(13):1137-1147. PubMed ID: 33951732
[TBL] [Abstract][Full Text] [Related]
10. Disease evolution and outcomes in familial AML with germline CEBPA mutations.
Tawana K; Wang J; Renneville A; Bödör C; Hills R; Loveday C; Savic A; Van Delft FW; Treleaven J; Georgiades P; Uglow E; Asou N; Uike N; Debeljak M; Jazbec J; Ancliff P; Gale R; Thomas X; Mialou V; Döhner K; Bullinger L; Mueller B; Pabst T; Stelljes M; Schlegelberger B; Wozniak E; Iqbal S; Okosun J; Araf S; Frank AK; Lauridsen FB; Porse B; Nerlov C; Owen C; Dokal I; Gribben J; Smith M; Preudhomme C; Chelala C; Cavenagh J; Fitzgibbon J
Blood; 2015 Sep; 126(10):1214-23. PubMed ID: 26162409
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
Wakita S; Sakaguchi M; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Tajika K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Kayamori K; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Marumo A; Omori I; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Kurosawa A; Mizoguchi A; Komatsu N; Fukuda T; Ohashi K; Kanda Y; Inokuchi K; Yamaguchi H
Blood Adv; 2022 Jan; 6(1):238-247. PubMed ID: 34448807
[TBL] [Abstract][Full Text] [Related]
12. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
[TBL] [Abstract][Full Text] [Related]
13. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
Wen XM; Lin J; Yang J; Yao DM; Deng ZQ; Tang CY; Xiao GF; Yang L; Ma JC; Hu JB; Qian W; Qian J
Int J Clin Exp Pathol; 2014; 7(10):6832-40. PubMed ID: 25400766
[TBL] [Abstract][Full Text] [Related]
14. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
Mendoza H; Podoltsev NA; Siddon AJ
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():86-95. PubMed ID: 34288448
[TBL] [Abstract][Full Text] [Related]
15. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
16. Genetic heterogeneity of cytogenetically normal AML with mutations of
Konstandin NP; Pastore F; Herold T; Dufour A; Rothenberg-Thurley M; Hinrichsen T; Ksienzyk B; Tschuri S; Schneider S; Hoster E; Berdel WE; Woermann BJ; Sauerland MC; Braess J; Bohlander SK; Klein HG; Hiddemann W; Metzeler KH; Spiekermann K
Blood Adv; 2018 Oct; 2(20):2724-2731. PubMed ID: 30337300
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.
Mizushima Y; Taki T; Shimada A; Yui Y; Hiraumi Y; Matsubara H; Watanabe M; Watanabe K; Kamitsuji Y; Hayashi Y; Tsukimoto I; Kobayashi R; Horibe K; Tawa A; Nakahata T; Adachi S
Int J Hematol; 2010 Jun; 91(5):831-7. PubMed ID: 20495894
[TBL] [Abstract][Full Text] [Related]
18. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
Greif PA; Dufour A; Konstandin NP; Ksienzyk B; Zellmeier E; Tizazu B; Sturm J; Benthaus T; Herold T; Yaghmaie M; Dörge P; Hopfner KP; Hauser A; Graf A; Krebs S; Blum H; Kakadia PM; Schneider S; Hoster E; Schneider F; Stanulla M; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
Blood; 2012 Jul; 120(2):395-403. PubMed ID: 22649106
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
Blood Cancer J; 2014 Jul; 4(7):e226. PubMed ID: 25014773
[TBL] [Abstract][Full Text] [Related]
20. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.
Green CL; Tawana K; Hills RK; Bödör C; Fitzgibbon J; Inglott S; Ancliff P; Burnett AK; Linch DC; Gale RE
Br J Haematol; 2013 Jun; 161(5):701-705. PubMed ID: 23560626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
